KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Change in Account Payables (2018 - 2025)

Historic Change in Account Payables for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $1.4 million.

  • Castle Biosciences' Change in Account Payables rose 16533.46% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 42043.15%. This contributed to the annual value of -$4.4 million for FY2024, which is 17660.77% down from last year.
  • Castle Biosciences' Change in Account Payables amounted to $1.4 million in Q3 2025, which was up 16533.46% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Change in Account Payables registered a high of $3.9 million during Q1 2023, and its lowest value of -$2.2 million during Q3 2024.
  • Its 5-year average for Change in Account Payables is $254210.5, with a median of -$40000.0 in 2021.
  • Per our database at Business Quant, Castle Biosciences' Change in Account Payables plummeted by 193571.43% in 2021 and then skyrocketed by 198342.25% in 2023.
  • Castle Biosciences' Change in Account Payables (Quarter) stood at -$855000.0 in 2021, then tumbled by 83.98% to -$1.6 million in 2022, then surged by 291.61% to $3.0 million in 2023, then crashed by 118.91% to -$570000.0 in 2024, then soared by 346.67% to $1.4 million in 2025.
  • Its Change in Account Payables was $1.4 million in Q3 2025, compared to $1.1 million in Q2 2025 and $615000.0 in Q1 2025.